Key result
In a 16-year-old boy with fulminant eosinophilic myocarditis, short-term use of a percutaneous ventricular assist device and immunosuppressive therapy improved left-ventricular ejection fraction from 27% to 47%.
Why the study?
Patients with eosinophilic myocarditis may benefit from mechanical circulatory support acting as a bridge to myocardial recovery in response to effective immunosuppressive therapy.
Case Report (n=1)
May support combined percutaneous ventricular assist device and immunosuppression in fulminant eosinophilic myocarditis; hypothesis-generating and leaves open need for prospective studies.
Eosinophilic myocarditis (EM) is a rare condition characterized by myocardial eosinophilic infiltration due to various underlying etiologies. The patient with EM may benefit from appropriate use of mechanical circulatory support (MCS) that acts as a bridge to myocardial recovery in response to effective immunosuppressive therapy. A 16-year-old boy presented with cardiogenic shock due to fulminant myocarditis, for which a percutaneous ventricular assist device (PVAD) was immediately inserted. Based on the histological diagnosis of EM, immunosuppressive therapy was immediately commenced, leading to improvement of left-ventricular ejection fraction (27% to 47%). The PVAD was successfully removed on day 7. Cardiac magnetic resonance imaging and dual-tracer myocardial scintigraphy suggested limited extent of irreversible myocardial damage. For fulminant EM, the short-term use of PVAD, together with immunosuppressive therapy guided by an immediate histological investigation, may be an effective bridging strategy to myocardial recovery.
No takes yet. Share an insight, caveat, or question.
Hasegawa-Tamba et al. (2019) conducted a case report in Fulminant Eosinophilic Myocarditis (n=1). Percutaneous ventricular assist device (PVAD) and immunosuppressive therapy was evaluated on Left-ventricular ejection fraction improvement. In a 16-year-old boy with fulminant eosinophilic myocarditis, short-term use of a percutaneous ventricular assist device and immunosuppressive therapy improved left-ventricular ejection fraction from 27% to 47%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: